Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania

Reference

• Gagiano C, Read S, Thorpe L, Eerdekens M, Van Hove I. Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders. Psychopharmacology 2005;179:629–36.
   PubMed Web of Science ®Google Scholar
• Purdon SE, Woodward N, Lindborg SR, Stip E. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology 2003;169:390–7.
   PubMed Web of Science ®Google Scholar
• Tierney E, Aman M, Stout D, Pappas K, Arnold LE, Vitiello B, . Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study. Psychopharmacology 2007;191:149–57.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Uchida H, Watanabe K, Nomura K, Takeuchi H, Tomita M, . How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone? A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology 2007;195:285–95.
   PubMed Web of Science ®Google Scholar
• Naber D, Greenspan A, Schreiner A. Efficacy and safety of risperidone in the treatment of elderly patients suffering from organic brain disease (organic brain syndrome): results from a double-blind, randomized, placebo-controlled clinical trial. Psychopharmacology 2007;191:1027–9.
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Kondo T, Suzuki A, Mihara K, Kaneko S. Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia. Psychopharmacology 2002; 162:63–6.
   PubMed Web of Science ®Google Scholar
• Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry 2005;187: 229–34.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Washington DC: American Psychiatric Association;1994.
   Google Scholar
• Bowden CL. Making optimal use of combination pharmacotherapy in bipolar disorder. J Clin Psychiatry 2004;65:21–4.
   PubMed Web of Science ®Google Scholar
• Schneider AL, Wilcox CS. Divalproate augmentation in lithium-resistant rapid cycling mania in four geriatric patients. J Affect Disord 1998;47:201–5.
   PubMed Web of Science ®Google Scholar
• Bowden CL. The effectiveness of divalproate in all forms of mania and the broader bipolar spectrum: many questions, few answers. J Affect Disord 2004;79:9–14.
   Web of Science ®Google Scholar
• Bowden CL, Singh V. Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr Scand 2005;426:13–20.
   Google Scholar
• Calabrese JR, Shelton MD, Rapport DJ, Kujawa M, Kimmel SE, Caban S. Current research on rapid cycling bipolar disorder and its treatment. J Affect Disord 2001;67:241–55.
   PubMed Web of Science ®Google Scholar
• Andrade C. A mood stabilizer with risperidone or haloperidol for mania. Am J Psychiatry 2004;161:2139–40.
   PubMedGoogle Scholar
• Bahk WM, Yoon JS, Kim YH, Lee YH, Lee C, Kim KS, . Risperidone in combination with mood stabilizers for acute mania: a multicentre, open study. Int Clin Psychopharmacol 2004;19:299–303.
   PubMed Web of Science ®Google Scholar
• Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005;15:75–84.
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Madhusoodanan S, Fuller MA, Aulakh L, Keaton DB. Risperidone for bipolar disorders. Expert Rev Neurother 2005;5:177–87.
   PubMedGoogle Scholar
• Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bodwen CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: adouble-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002;159:1146–54.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran R.Mood stabilizers plus risperidone or placebo in the treatment of acute mania. Br J Psychiatry 2003;182:141–7.
   PubMed Web of Science ®Google Scholar
• Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, . A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60(12): 1218–26.
   PubMed Web of Science ®Google Scholar
• Tsai JH, Tang TC, Yang P, Yen CF, Yang MJ, Yen JY, . Adjunctive treatment of acute mania with risperidone versus typical antipsychotics: a retrospective study. Kaohsiung J Med Sci 2005;21:539–44.
   PubMedGoogle Scholar
• Squassina A, Manchia M, Del Zompo M. Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder. Hum Genom Proteomics 2010;2:159761.
   Google Scholar
• Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429–35.
   PubMed Web of Science ®Google Scholar
• Ventura MA, Green MF, Shaner A, Liberman RP. Training and quality assurance with the brief psychiatric rating scale: The drift buster. Int J Methods Psychiatr Res 1993;3:221–44.
   Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology – Revised. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. p 218–22.
   Google Scholar
• Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7:233.
   Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
   PubMed Web of Science ®Google Scholar
• Sadock BJ, Sadock VA. Schizophrenia. Kaplan & Sadock's comprehensive textbook of psychiatry. 7th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2000. p 1096–231.
   Google Scholar
• Thomas A, Donnell AJ, Young TR. Factor structure and differential validity of the expanded Brief Psychiatric Rating Scale. Assessment 2004;11:177–87.
   PubMed Web of Science ®Google Scholar
• Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry 2005;187:366–71.
   PubMed Web of Science ®Google Scholar
• Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005;76: 247–65.
   PubMed Web of Science ®Google Scholar
• Pancheri P, Picardi A, Pasquini M, Gaetano P, Biondi M. Psychopathological dimensions of depression: A factor study of the 17-item Hamilton depression rating scale in unipolar depressed outpatients. J Affect Disord 2002;68:41–7.
   PubMed Web of Science ®Google Scholar
• Miller DS, Yatham LN, Lam RW. Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania. J Clin Psychiatry 2001;62:975–80.
   PubMed Web of Science ®Google Scholar
• Petrie W. Risperidone versus olanzapine as adjunctive therapy in the treatment of patients with bipolar disorder who arereceiving a primary thymoleptic agent Poster at the 44th annual meeting of the New Clinical Drug Evaluation Unit(NCDEU), Arizona, US; 2004.
   Google Scholar
• Guzelcan Y, de Haan L, Scholte WF. Risperidone may induce mania. Psychopharmacology 2002;162:85–6.
   PubMed Web of Science ®Google Scholar
• Patel V. Ethics of placebo-controlled trial in severe mania. Ind J Med Ethics 2006;3:11–2.
   PubMedGoogle Scholar
• Simon R. Are placebo-controlled clinical trials ethical or needed when alternative treatment exists? Ann Intern Med 2000;133:474–5.
   PubMed Web of Science ®Google Scholar
• Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med 2000;133:464–70.
   PubMed Web of Science ®Google Scholar